EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Solh, M, Bahlis, NJ, Raje, NS, Costello, CL, Dholaria, B, Levy, MY, Tomasson, MH, Dube, H, Damore, MA, Lon, HK, Basu, C, Skoura, A, Chan, EM, Trudel, S, Jakubowiak, A, Chu, MP, Gasparetto, C, Dalovisio, A, Sebag, M, Lesokhin, AM
Published in Hematology, Transfusion and Cell Therapy (01.10.2021)
Published in Hematology, Transfusion and Cell Therapy (01.10.2021)
Get full text
Journal Article
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
Published in British journal of haematology (01.03.2018)
Published in British journal of haematology (01.03.2018)
Get full text
Journal Article